Rafferty Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.37M Sell
354,260
-28,296
-7% -$220K 0.01% 496
2025
Q4
$2.98M Buy
382,556
+13,234
+4% +$95.7K 0.01% 558
2025
Q3
$2.8M Buy
369,322
+68,371
+23% +$569K 0.01% 562
2025
Q2
$2.7M Buy
300,951
+47,626
+19% +$444K 0.01% 537
2025
Q1
$1.9M Buy
253,325
+18,489
+8% +$149K 0.01% 592
2024
Q4
$1.77M Sell
234,836
-136,198
-37% -$1.03M 0.01% 676
2024
Q3
$2.82M Sell
371,034
-94,697
-20% -$720K 0.01% 552
2024
Q2
$2.88M Sell
465,731
-1,104,051
-70% -$6.09M 0.01% 539
2024
Q1
$7.97M Buy
1,569,782
+614,195
+64% +$3.45M 0.03% 347
2023
Q4
$5.72M Buy
955,587
+147,699
+18% +$856K 0.02% 420
2023
Q3
$5.72M Sell
807,888
-167,075
-17% -$1.2M 0.03% 361
2023
Q2
$6.86M Buy
974,963
+154,442
+19% +$1.24M 0.04% 348
2023
Q1
$6.84M Buy
820,521
+52,448
+7% +$505K 0.05% 299
2022
Q4
$8.82M Buy
768,073
+252,845
+49% +$3.15M 0.07% 219
2022
Q3
$6.49M Buy
515,228
+127,901
+33% +$1.65M 0.07% 251
2022
Q2
$4.1M Buy
387,327
+55,614
+17% +$574K 0.04% 318
2022
Q1
$5.39M Sell
331,713
-120,924
-27% -$1.94M 0.03% 373
2021
Q4
$6.27M Buy
452,637
+247,639
+121% +$3.28M 0.03% 290
2021
Q3
$2.95M Buy
204,998
+48,891
+31% +$771K 0.02% 486
2021
Q2
$2.47M Sell
156,107
-107,477
-41% -$1.46M 0.02% 611
2021
Q1
$2.68M Buy
263,584
+151,233
+135% +$1.56M 0.02% 550
2020
Q4
$837K Sell
112,351
-413,951
-79% -$2.13M 0.01% 555
2020
Q3
$1.81M Buy
526,302
+303,685
+136% +$1.3M 0.02% 449
2020
Q2
$1.06M Buy
222,617
+205,417
+1,194% +$820K 0.01% 528
2020
Q1
$34K Sell
17,200
-128,884
-88% -$355K ﹤0.01% 584
2019
Q4
$504K Sell
146,084
-125,292
-46% -$315K 0.01% 687
2019
Q3
$777K Sell
271,376
-109,118
-29% -$339K 0.01% 592
2019
Q2
$1.44M Buy
380,494
+275,454
+262% +$1.66M 0.03% 496
2019
Q1
$855K Buy
+105,040
New +$899K 0.01% 580

Other funds holding BCRX